- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07385209
Design and Application of a Home Care WeChat Mini-Program for Children After Congenital Heart Disease Surgery (CHD-HomeCare)
Design and Application of a Home Care Mini-Program for Children With Congenital Heart Disease After Discharge: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Background and Rationale Congenital heart disease (CHD) is the most common birth defect globally, with a high prevalence in China. While surgical advances have significantly improved survival rates, CHD has transitioned into a chronic condition requiring long-term management. The post-discharge period places immense stress on families, affecting caregiver well-being, family functioning, and the child's recovery. Existing home care models often focus on the child's deficits or rely on resource-intensive methods (e.g., home visits). Guided by the Double ABC-X model of family adaptation, this study adopts a family strengths-based perspective. It aims to develop and test a digital, interactive home care mini-program designed to support family resources, promote positive adaptation, and improve health outcomes after CHD surgery.
Study Objectives Primary Objective: To evaluate the effectiveness of a family-centered, WeChat-based home care mini-program on improving family health in households with children after CHD surgery.
Secondary Objectives: To assess the program's impact on: 1) reducing family stress, 2) enhancing the quality of life of both the child and primary caregivers, and 3) improving the child's physiological recovery indicators.
- Study Design This is a prospective, two-arm, parallel-group, assessor-blinded, randomized controlled trial (RCT). Participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group.
Participants, Setting, and Timeline Participants: Families (the child who underwent surgery and their primary caregiver/parent) of children (≤12 years old) with CHD after surgical intervention.
Setting: Recruitment and baseline assessment will be conducted at a tertiary hospital in Yunnan Province, China. The intervention and follow-up will be home-based.
Sample Size: 210 families (105 per group), calculated with 80% power, a significance level of 0.05, an effect size (δ/σ) of 0.5, and accounting for 20% attrition.
Timeline:
Study Start Date (first enrollment): December 2025.
Primary Completion Date (last participant's final data collection for primary outcome): December 2026.
Study Completion Date: January 2027.
Interventions
Intervention Group: Will receive access to the "CHD Postoperative Home Care" WeChat mini-program in addition to routine care. The mini-program includes three core modules:
Education Module: Provides multimedia (text, images, video) health information on post-operative care, nutrition, medication, activity guidance, and complication monitoring.
Interactive Support Module: Features a secure peer-support community for sharing experiences (digital narrative therapy) and a direct communication channel for families to consult the healthcare team.
Monitoring & Alert Module: Allows families to log and submit key health data (e.g., weight, symptoms). The system includes automated alerts for concerning values and prompts for scheduled follow-up assessments. The research team will remotely monitor this data and initiate follow-up calls if alerts are triggered.
Control Group: Will receive routine postoperative care, which includes standard discharge instructions and scheduled telephone follow-ups by hospital staff at 1, 3, and 6 months post-discharge.
Outcome Measures and Assessment Timepoints Assessments will occur at baseline (T0, pre-discharge) and at 1 (T1), 3 (T2), and 6 (T3) months post-discharge.
Primary Outcomes:
Family Health: Measured by the Chinese version of the Family Health Scale (FHS).
Family Stress: Measured by the Congenital Heart Disease Family Stressor Scale.
Quality of Life of Caregivers: Measured by the 36-Item Short Form Health Survey (SF-36).
Quality of Life of the Child: Measured by the Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cardiac Module.
Secondary Outcomes (Child Physiological Measures):
Functional Capacity: 6-Minute Walk Test distance.
Growth: Body weight.
Cardiac Function: Heart rate and Left Ventricular Ejection Fraction (via echocardiogram).
Randomization, Blinding, and Data Analysis
Randomization: After baseline assessment, eligible families will be randomly assigned using computer-generated random numbers sealed in opaque envelopes.
Blinding: Outcome assessors and data analysts will be blinded to group allocation. Due to the nature of the intervention, participants and intervention facilitators cannot be blinded.
Statistical Analysis: Data will be analyzed using SPSS software. Baseline characteristics will be compared using t-tests, chi-square, or Mann-Whitney U tests. Primary and secondary outcomes will be analyzed using Linear Mixed Models (LMM) for repeated measures to examine group, time, and interaction effects.
- Ethical Considerations The study protocol has been submitted for approval to the Institutional Review Board of Kunming Medical University. Written informed consent will be obtained from all participating caregivers. The study will adhere to principles of confidentiality, beneficence, and the right to withdraw without penalty.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ruijie YangLan, Graduate Student
- Phone Number: +86-18887278258
- Email: 1052076436@qq.com
Study Contact Backup
- Name: Fang Ma,, Director Nurse
- Phone Number: +86-15925189957
- Email: rebeccamalei@126.com
Study Locations
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- First Affiliated Hospital of Kunming Medical University
-
Contact:
- Fang Ma, professor of nursing
- Phone Number: +86 18887278258
- Email: 1052076436@qq.com
-
Contact:
- ruijie YangLan, postgraduate student
- Phone Number: +86 18887278258
- Email: 1052076436@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - The child is ≤12 years old.
- The child has been diagnosed with congenital heart disease (CHD) and is scheduled for or has undergone corrective surgery.
- The child is in a stable medical condition (non-acute phase).
- At least one primary caregiver (parent or sibling >12 years old) of the child agrees to participate.
- The caregiver provides written informed consent to participate in the study.
Exclusion Criteria:
- - The child has severe developmental defects.
- The child has other major diseases that significantly affect quality of life.
- The caregiver has visual, hearing, or cognitive impairments that hinder communication.
- The caregiver has a diagnosed psychiatric disorder.
- The caregiver is unconscious or otherwise unable to provide consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
Participants receiving the WeChat mini-program intervention.
|
Participants in this group will receive standard post-discharge care as per hospital protocol, which includes initial discharge education and scheduled telephone follow-ups by hospital staff at 1, 3, and 6 months post-discharge to assess the child's status and answer questions.
|
|
Active Comparator: Control Group
Participants receiving routine care with telephone follow-up.
|
A family-centered WeChat mini-program providing health education, peer support, and remote monitoring for post-operative care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Family Health Score
Time Frame: Change from Baseline at 6 months post-discharge
|
Score on the Chinese version of the Family Health Scale (FHS).
|
Change from Baseline at 6 months post-discharge
|
|
Family Stress Score
Time Frame: Change from Baseline at 6 months post-discharge
|
Score on the Congenital Heart Disease Family Stressor Scale.
|
Change from Baseline at 6 months post-discharge
|
|
Child's Quality of Life Score
Time Frame: Change from Baseline at 6 months post-discharge
|
Score on the Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cardiac Module.
|
Change from Baseline at 6 months post-discharge
|
|
Caregiver's Quality of Life Score
Time Frame: Change from Baseline at 6 months post-discharge
|
Score on the 36-Item Short Form Health Survey (SF-36).
|
Change from Baseline at 6 months post-discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Weight
Time Frame: Measured at 1, 3, and 6 months post-discharge
|
Body weight measured in kilograms.
|
Measured at 1, 3, and 6 months post-discharge
|
|
Left Ventricular Ejection Fraction
Time Frame: Measured at 6 months post-discharge
|
Percentage measured by echocardiogram.
|
Measured at 6 months post-discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fang Ma,, professor of nursing, First Affiliated Hospital of Kunming Medical University
- Principal Investigator: Fang Ma, professor of nursing, First Affiliated Hospital of Kunming Medical University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025L393
- 72364022 (Other Identifier: National Natural Science Foundation of China)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAdult Congenital Heart Disease | Congenital Heart Disease (CHD) | Pediatric Congenital Heart Disease | Heart Transplant PatientsItaly
-
Seoul National University HospitalUniversity of SeoulNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD) | Complex Congenital Heart DiseaseKorea, Republic of
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
China National Center for Cardiovascular DiseasesPeking University; Shandong University; Guangxi Medical University; Wenzhou Medical... and other collaboratorsActive, not recruitingStructural Heart Disease | Congenital Heart Disease (CHD)China
-
The Children's Hospital of Zhejiang University...Beijing Children's Hospital; Children's Hospital of Nanjing Medical UniversityNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD)China
-
Martin SchweigerUniversity Children's Hospital, ZurichRecruitingFontan Physiology | Congenital Heart Disease in Children | Congenital Heart SurgerySwitzerland
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
University Hospital, BordeauxNot yet recruitingCHD - Congenital Heart DiseaseFrance
-
Leiden University Medical CenterRecruitingAdult Congenital Heart DiseaseNetherlands
-
Cairo UniversityNot yet recruiting
Clinical Trials on Routine Care with Telephone Follow-up
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Bassett HealthcareActive, not recruitingAntineoplastic AgentsUnited States
-
University of Sao PauloCompletedCoronary Artery Disease | Percutaneous Coronary InterventionBrazil
-
Boston Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular DiseasesUnited States
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Wenzhou Medical University; Jinhua Central Hospital and other collaboratorsRecruitingCoronary Artery DiseaseChina
-
Aalborg University HospitalRecruiting
-
St. Justine's HospitalCompleted
-
National Taipei University of Nursing and Health...Yuan's General HospitalCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland